Trial Profile
A Phase 2 Open-Label Proof of Concept Study to Assess the Efficacy, Safety, and Pharmacokinetics of ACH-0144471 in Untreated Patients With Paroxysmal Nocturnal Hemoglobinuria
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2023
Price :
$35
*
At a glance
- Drugs Danicopan (Primary)
- Indications Paroxysmal nocturnal haemoglobinuria
- Focus Proof of concept; Therapeutic Use
- Sponsors Alexion AstraZeneca Rare Disease; Alexion Pharmaceuticals
- 06 Nov 2019 Results released at the 61st Annual Meeting and Exposition of the American Society of Hematology
- 06 Nov 2019 According to an Achillion Pharmaceuticals media release, data from this study will be presented at the 61stAmerican Society of Hematology (ASH) Annual Meeting.
- 10 Jun 2019 Results presented in an Achillion Pharmaceuticals media release.